Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to support the ASLAN to further investigate their clinical development of ASLAN004 (eblasakimab), which is being evaluated in the mid-stage clinical trial for the treating atopic dermatitis.
Lead Product(s): Eblasakimab
Therapeutic Area: Dermatology Product Name: ASLAN004
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: ASLAN Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 02, 2024
Details:
Rituxan (rituximab) is an anti-CD20 monoclonal antibody that specifically binds to CD20, a protein expressed on B cells, excluding hematopoietic stem cells and plasma cells, which is used for the treatment of Lupus Nephritis.
Lead Product(s): Rituximab
Therapeutic Area: Nephrology Product Name: Rituxan
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details:
Under the agreement, Zenyaku gains exclusive rights to develop and commercialize ASLAN004 (eblasakimab), a potential first-in-class monoclonal antibody targeting the IL‑13 receptor subunit, in atopic dermatitis (AD) and all other indications in Japan.
Lead Product(s): Eblasakimab
Therapeutic Area: Dermatology Product Name: ASLAN004
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: ASLAN Pharmaceuticals
Deal Size: $138.5 million Upfront Cash: $12.0 million
Deal Type: Licensing Agreement June 22, 2023
Details:
Rituxan (rituximab) is an anti-CD20 monoclonal antibody that specifically binds to CD20, a protein expressed on B cells, excluding stem cells and plasma cells. It attacks target B cells using the immune system equipped with the human body, and damages cells.
Lead Product(s): Rituximab
Therapeutic Area: Rare Diseases and Disorders Product Name: Rituxan
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2022
Details:
Rituxan, an anti-CD20 monoclonal antibody got approval in additional indications of refractory pemphigus vulgaris and pemphigus foliaceus by MHLW based on results of investigator-initiated phase II clinical trial in Japan of KCTR-D006 study and PEMPHIX study.
Lead Product(s): Rituximab
Therapeutic Area: Immunology Product Name: Rituxan
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 24, 2021